Rapid Eye Movement Sleep Behavior Disorder (RBD), as categorized in the DSM-5-TR (American Psychiatric Association [APA], 2023), is a sleep disorder characterized by the loss of muscle atonia (muscle relaxation) during rapid eye movement (REM) sleep. This condition typically results in physical behaviors during REM sleep stages, often mirroring the actions occurring in dreams. Individuals with RBD may exhibit various behaviors, such as talking, yelling, punching, kicking, sitting up in bed, jumping out of bed, or even more complex activities. These behaviors are often potentially harmful to the individual or their bed partner (Schenck et al., 2013).

Unlike other sleep disorders, RBD is unique in its direct interaction with REM sleep. During normal REM sleep, a person experiences atonia, preventing them from acting out their dreams. However, this atonia is absent or incomplete in RBD, leading to the enactment of dreams (Postuma et al., 2012). The content of these dreams often involves intense, vivid, or violent themes, which are reflected in the physical activities (Frauscher et al., 2014).

People with RBD may not be aware of their behaviors unless they cause injury or are told by others. The disorder is more common in older adults and is often associated with neurodegenerative disorders, such as Parkinson's disease and Lewy body dementia (Iranzo et al., 2014). However, it can also occur in the absence of neurological disorders. It is essential to differentiate RBD from other sleep disorders like sleepwalking, as the management and implications can be pretty different (Schenck & Mahowald, 2002).

In conclusion, Rapid Eye Movement Sleep Behavior Disorder is a significant condition that can substantially impact the quality of life and safety of those affected. Its association with neurodegenerative diseases makes early recognition and management critical.

Diagnostic Criteria

Rapid Eye Movement Sleep Behavior Disorder (RBD), as outlined in the DSM-5-TR (APA, 2013), is diagnosed based on specific criteria. These include the presence of REM sleep without atonia (RSWA), as confirmed by polysomnographic recordings, and episodes of sleep-related vocalization or complex motor behaviors during REM sleep (American Psychiatric Association, 2023). These behaviors during sleep are typically more vigorous than typical REM-related twitches and are often associated with dream enactment.

The diagnostic criteria also emphasize the clinical significance of these behaviors, which can result in harm or distress to the individual or the bed partner (Schenck et al., 2013). Another sleep disorder, mental disorder, medical condition, medication, or substance use does not better explain the disorder. It is essential to distinguish RBD from other parasomnias, such as sleepwalking, as each has distinct management and implications (Schenck & Mahowald, 2002).

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR), published by the American Psychiatric Association, does not provide specific specifiers for Rapid Eye Movement Sleep Behavior Disorder (RBD). Specifiers in DSM-5-TR are usually additional labels or descriptors that can be applied to a diagnosis to categorize further and describe the disorder's manifestation and characteristics.

In the case of RBD, the DSM-5-TR focuses on the primary diagnostic criteria, which include behaviors indicative of dream enactment during REM sleep and evidence of REM sleep without atonia (RSWA) from polysomnographic recordings. The diagnostic criteria emphasize the presence of these behaviors, their impact on sleep and safety, and the need to differentiate RBD from other sleep disorders or conditions.

While there are no specific specifiers for RBD in the DSM-5-TR, clinicians often consider various aspects of the disorder when making a diagnosis and planning treatment. These may include:

• Severity and Frequency of Symptoms: The intensity and regularity of dream enactment behaviors can vary greatly among individuals with RBD.
• Associated Neurological Disorders: RBD is often associated with neurodegenerative disorders, such as Parkinson’s disease and Lewy body dementia. The presence of these disorders can be a crucial aspect of the clinical picture.
• Response to Treatment: How an individual responds to treatment, such as medications like clonazepam or melatonin, can also be an essential consideration.
• Risk of Injury: The potential for injury to the individual or bed partner due to violent or vigorous behaviors during sleep is a critical concern and can influence management strategies.
• Onset: Whether the onset of RBD is acute or chronic, or if it is related to medication or substance use, can be relevant for the clinical understanding of the disorder.

For the most accurate and up-to-date information, referring directly to the DSM-5-TR or consulting with a healthcare professional specializing in sleep disorders is recommended.

Research has shown that individuals with RBD frequently experience dreams with aggressive or action-packed themes, which align with their physical activities during sleep (Postuma et al., 2012). Studies also indicate a strong association between RBD and neurodegenerative disorders, particularly Parkinson’s disease and Lewy body dementia, suggesting that RBD can be an early indicator of these conditions (Iranzo et al., 2014).

Furthermore, studies utilizing polysomnography have been instrumental in understanding the pathophysiology of RBD, demonstrating the absence of normal skeletal muscle atonia during REM sleep in affected individuals (Frauscher et al., 2014). This objective finding is crucial for differentiating RBD from other sleep disorders and supports its unique pathophysiological mechanism.

In summary, the diagnosis of RBD as per DSM-5-TR criteria relies heavily on clinical history, characteristic polysomnographic findings, and the exclusion of other conditions. Ongoing research continues to deepen the understanding of this disorder and its potential implications for neurodegenerative diseases.

The Impacts

Rapid Eye Movement Sleep Behavior Disorder (RBD) has several significant impacts on the individual experiencing the disorder and their bed partner. The primary concern in RBD is the physical enactment of dreams, which can lead to injuries. A study by Schenck, Boeve, and Mahowald (2013) reported that patients with RBD can engage in activities like punching, kicking, or leaping out of bed, often resulting in harm to themselves or their sleeping partners. These behaviors can lead to severe injuries, including fractures and lacerations, which significantly affect the quality of life.

Another crucial impact of RBD is its association with neurodegenerative diseases. Iranzo et al. (2014) conducted a study revealing that individuals with RBD have a higher risk of developing conditions such as Parkinson's disease and Lewy body dementia. This finding suggests that RBD can be an early marker of these neurodegenerative disorders, highlighting the importance of monitoring and managing RBD in patients.

Furthermore, the sleep disturbances caused by RBD can lead to daytime sleepiness and fatigue, affecting an individual's ability to perform daily activities. A study by Postuma et al. (2012) demonstrated that RBD significantly disrupts sleep patterns, leading to sleep fragmentation and decreased sleep efficiency. This disruption can contribute to cognitive impairments and mood disturbances, diminishing quality of life.

Additionally, RBD can have a substantial emotional and psychological impact. The fear of causing harm or embarrassment due to RBD behaviors can lead to anxiety and social isolation. Boeve et al. (2013) found that patients with RBD might experience embarrassment about their sleep behaviors, leading to reluctance to discuss symptoms with healthcare providers or even avoiding sleeping in the same bed as a partner.

In summary, RBD has far-reaching implications, affecting physical safety, mental health, and quality of life. Its potential as a precursor to neurodegenerative diseases makes early recognition and management essential.

The Etiology (Origins and Causes)

The etiology of Rapid Eye Movement Sleep Behavior Disorder (RBD) involves a complex interplay of neurophysiological, genetic, and environmental factors. At its core, RBD is characterized by a malfunction in the brain mechanisms that regulate REM sleep, particularly the normal paralysis during this phase.

Neurophysiologically, RBD is associated with dysfunctions in the brainstem, where REM sleep is regulated. Studies have shown that lesions in the pontine region of the brainstem, which controls REM sleep atonia, can lead to RBD symptoms (Boeve et al., 2013). This suggests that disruptions in the neural pathways responsible for maintaining muscle atonia during REM sleep are central to the disorder's pathophysiology.

Genetically, while there is no clear-cut hereditary pattern for RBD, research indicates a possible genetic component. Postuma et al. (2012) highlighted that specific genetic markers might increase the susceptibility to RBD, though these findings are preliminary and require further exploration.

Environmental factors also play a role in the development of RBD. Certain medications, particularly those affecting the central nervous system, such as antidepressants, have been associated with the onset of RBD symptoms (Iranzo et al., 2014). Additionally, lifestyle factors such as alcohol and tobacco use have been linked to an increased risk of RBD, though the exact mechanisms are not yet fully understood.

The association of RBD with neurodegenerative disorders, particularly synucleinopathies like Parkinson's disease and Lewy body dementia, is a critical area of research. Schenck, Boeve, and Mahowald (2013) noted that a significant percentage of individuals with RBD develop a neurodegenerative disorder later in life. This suggests that RBD may be an early indicator of underlying neurodegenerative processes.

In conclusion, RBD arises from disrupted brainstem functions, possible genetic predispositions, and environmental influences. Its strong association with neurodegenerative diseases underscores the importance of understanding its etiology for early detection and intervention in these conditions.

Comorbidities

Rapid Eye Movement Sleep Behavior Disorder (RBD) is often associated with various comorbidities, particularly neurodegenerative diseases, sleep disorders, and psychiatric conditions. A significant aspect of RBD research focuses on its relationship with neurodegenerative disorders.

One of the most notable comorbidities of RBD is its strong association with neurodegenerative diseases, especially synucleinopathies like Parkinson's disease and Lewy body dementia. A landmark study by Schenck, Boeve, and Mahowald (2013) found that a significant percentage of patients initially diagnosed with RBD developed a neurodegenerative disorder over time. This study highlighted RBD as a potential early marker for these conditions, providing a critical window for early intervention and management.

In addition to neurodegenerative diseases, RBD has been linked to other sleep disorders. Iranzo et al. (2014) conducted research showing that patients with RBD often experience obstructive sleep apnea, periodic limb movement disorder, and insomnia. These concurrent sleep disturbances can exacerbate the symptoms of RBD and further impair the quality of life.

Psychiatric comorbidities are also prevalent in individuals with RBD. Studies have shown an increased incidence of depression and anxiety disorders in RBD patients. Postuma et al. (2012) found that these psychiatric conditions can significantly impact the overall well-being of RBD patients, complicating the clinical management of the disorder.

Furthermore, RBD has been associated with cognitive impairment. Boeve et al. (2013) reported that cognitive decline, ranging from mild cognitive impairment to overt dementia, is a common comorbidity in RBD patients. This relationship further underscores the potential link between RBD and neurodegenerative processes.

In summary, RBD is associated with a range of comorbidities, including neurodegenerative diseases, other sleep disorders, and psychiatric conditions. Understanding these comorbidities is essential for comprehensive management and offers insights into the potential progression of RBD to more severe neurological conditions.

Risk Factors

Several risk factors, including age, gender, neurodegenerative disease, and lifestyle factors, influence Rapid Eye Movement Sleep Behavior Disorder (RBD). Extensive research has been conducted to understand these risk factors and their impact on the development of RBD.

Age is a significant risk factor for RBD, with most patients diagnosed in their later years. Schenck, Boeve, and Mahowald (2013) found that the prevalence of RBD increases with age, with most cases diagnosed in individuals over 50 years. This trend suggests an age-related degeneration of brain structures involved in REM sleep regulation.

Gender also plays a role, with a higher prevalence of RBD reported in men. In a study by Boeve et al. (2013), it was observed that males are more frequently diagnosed with RBD than females, although the reasons for this gender disparity are not yet fully understood.

Neurodegenerative diseases, particularly Parkinson's disease and Lewy body dementia, are strongly associated with RBD. Iranzo et al. (2014) reported that individuals with RBD have a higher risk of developing these neurodegenerative conditions later in life. This association underscores the importance of monitoring RBD patients for signs of neurodegeneration.

Lifestyle factors, including smoking and alcohol consumption, have also been linked to RBD. Postuma et al. (2012) found that these factors can influence the onset and severity of RBD, although the exact mechanisms through which they contribute to the disorder are still being explored.

Additionally, certain medications, especially those affecting the central nervous system, can increase the risk of developing RBD. Medications like antidepressants have been associated with the onset or worsening of RBD symptoms, as highlighted in research by Frauscher et al. (2014).

In summary, RBD is a multifactorial disorder influenced by age, gender, neurological health, and lifestyle choices. Understanding these risk factors is crucial for early identification and management of RBD and for providing targeted interventions to at-risk populations.

Case Study

Presenting Complaint: Dave, age 31, complained of sleep disturbances, specifically involving episodes of 'acting out' his dreams. These episodes included talking, yelling, and sometimes moving his limbs in a manner that seemed to reflect dream content. Over the past six months, he reported these incidents occurring several times a month.

History: Dave's wife first noticed these behaviors approximately six months ago. Initially, they were infrequent but gradually increased in frequency. Dave mentioned that these episodes often involved dreams where he was defending himself or escaping from danger. Upon waking, he had no recollection of these events, only becoming aware of them through his wife's observations.

Medical and Psychiatric History: Dave has no known neurological disorders or psychiatric conditions history. He does not use recreational drugs and consumes alcohol socially. His medical history is unremarkable, with no chronic conditions or regular medication use.

Family History: There is no family history of sleep disorders or neurodegenerative diseases.

Mental Status Examination: Dave appeared well-groomed and cooperative. His speech was coherent and goal-directed. He exhibited no signs of hallucinations, delusions, or thought disorders. His mood was described as "generally good" with appropriate affect.

Physical and Neurological Examination: A general physical and neurological examination revealed no abnormalities. Dave's motor and sensory functions were intact, and no signs of parkinsonism were observed.

Investigations: Dave underwent polysomnographic evaluation, which showed increased muscle activity during REM sleep, consistent with REM Sleep Behavior Disorder (RBD). Other sleep stages were normal; no evidence of sleep apnea or periodic limb movement disorder was found.

Diagnosis: Based on the clinical history, spouse's reports, and polysomnographic findings, Dave was diagnosed with REM Sleep Behavior Disorder as per DSM-5-TR criteria.

Treatment and Management: Dave was advised on safety measures for his sleeping environment to prevent injury. He was started on a low dose of clonazepam before bedtime, which is often effective in reducing RBD symptoms. He was also referred to a sleep specialist for ongoing management and to monitor for any signs of neurodegenerative disorders, given the association between RBD and conditions like Parkinson's disease.

Follow-up: Dave reported a significant reduction in dream-enactment behaviors at a follow-up appointment three months later. His wife confirmed these observations. The treatment was well-tolerated, and no side effects were reported. Dave will continue with regular follow-ups to monitor his condition and potential developments.

Discussion: This case highlights the typical presentation of RBD in a relatively young patient without an apparent neurodegenerative disorder. Its potential association with future neurological conditions underscores the importance of thorough assessment and early intervention in managing RBD. Safety in the sleeping environment and appropriate pharmacological management are critical treatment components. Regular follow-up is essential for monitoring the effectiveness of treatment and the potential emergence of associated neurodegenerative disorders.

Recent Psychology Research Findings

Rapid Eye Movement Sleep Behavior Disorder (RBD) has been the subject of extensive psychological research, with studies focusing on its association with neurodegenerative diseases, its impact on cognitive functioning, and treatment efficacy.

One of the most significant findings in RBD research is its strong association with neurodegenerative disorders, particularly Parkinson's disease and Lewy body dementia. A groundbreaking study by Schenck, Boeve, and Mahowald (2013) followed a cohort of RBD patients over 16 years and found that 81% of them developed a neurodegenerative disorder. This study provided compelling evidence that RBD can be a prodromal symptom of these conditions, highlighting the need for ongoing neurological monitoring in RBD patients.

Cognitive impairment in RBD patients has also been a critical focus. Postuma et al. (2012) conducted a study assessing cognitive function in RBD patients and found that they showed higher rates of mild cognitive impairment than controls. This finding suggests that RBD may be linked to cognitive decline, potentially acting as an early marker of neurodegenerative processes affecting cognitive domains.

Treatment efficacy, particularly pharmacological interventions, has been another important area of research. A study by McCarter et al. (2013) evaluated the effectiveness of melatonin and clonazepam in managing RBD symptoms. The study found that both medications effectively reduced dream enactment behaviors, with melatonin having a better side effect profile. This research has important implications for the clinical management of RBD, providing evidence-based guidance for treatment options.

Furthermore, the relationship between RBD and psychiatric disorders has been explored. Iranzo et al. (2014) investigated the prevalence of depression and anxiety in RBD patients. Their study revealed a higher incidence of these psychiatric conditions in the RBD population, suggesting a complex interplay between sleep disturbances and mental health.

In summary, psychological research on RBD has provided crucial insights into its association with neurodegenerative diseases, cognitive implications, treatment strategies, and comorbid psychiatric conditions. These findings have significant implications for the early detection, management, and understanding of RBD.

Treatment and Interventions

The treatment and intervention of Rapid Eye Movement Sleep Behavior Disorder (RBD) involve a combination of pharmacological and non-pharmacological approaches, with the primary goals being to reduce the frequency and severity of dream-enactment behaviors and to ensure safety during sleep.

One of the most commonly prescribed pharmacological treatments for RBD is clonazepam, a benzodiazepine. McCarter, St Louis, and Boeve (2013) conducted a study assessing the efficacy of clonazepam in RBD patients. They found that it significantly reduced dream-enactment behaviors in a majority of cases. The study also noted that clonazepam was generally well-tolerated, although some patients experienced side effects such as daytime drowsiness and decreased balance.

Melatonin, a naturally occurring hormone, has also been studied as a treatment for RBD. Kunz and Bes (2009) investigated the effects of melatonin in managing RBD symptoms. Their study showed that melatonin effectively reduced the frequency and severity of RBD episodes. As reported in the study, an added benefit of melatonin was its safety profile, with fewer side effects compared to clonazepam.

In addition to pharmacological interventions, non-pharmacological strategies are crucial in managing RBD. This includes modifications to the sleep environment to prevent injury, such as padding the edges of the bed, removing potentially harmful objects from the bedroom, and using bed rails. These safety measures are essential given the risk of injury associated with RBD behaviors.

Cognitive-behavioral therapy (CBT) for insomnia has also been explored as an adjunct treatment for RBD. A study by Howell et al. (2011) demonstrated that CBT could improve sleep quality in RBD patients, potentially reducing the intensity of RBD symptoms. This approach focuses on addressing sleep-related anxiety and improving sleep hygiene, which can benefit overall sleep quality.

Lastly, regular follow-up and monitoring are crucial, especially considering the association between RBD and neurodegenerative disorders. This involves ongoing assessment of sleep behaviors and cognitive function and adjustments to treatment as needed.

In conclusion, the treatment of RBD is multifaceted, involving both medication and lifestyle modifications. Treatment choice depends on the individual's specific symptoms, response to medication, and overall health profile.

Implications if Untreated

Leaving Rapid Eye Movement Sleep Behavior Disorder (RBD) untreated can have several implications, ranging from immediate physical risks to long-term neurological consequences. A significant body of research has been dedicated to understanding these implications.

The immediate and perhaps most apparent risk of untreated RBD is physical injury. Patients with RBD can engage in vigorous activities such as punching, kicking, or jumping out of bed, mirroring their dream actions. A study by Boeve et al. (2013) highlighted that untreated RBD poses a risk of injury not only to the patients themselves but also to their bed partners. This study reported instances of patients and their partners sustaining injuries, some of which were severe, due to violent actions during sleep.

Another critical implication of untreated RBD is its strong association with neurodegenerative disorders. Schenck, Boeve, and Mahowald’s (2013) longitudinal study demonstrated that a significant proportion of RBD patients eventually developed neurodegenerative conditions like Parkinson's disease and dementia. This finding suggests that untreated RBD might be a precursor or an early warning sign of these disorders, highlighting the importance of regular neurological assessments for RBD patients.

Furthermore, the impact of untreated RBD on mental health should not be underestimated. Studies have shown that RBD can significantly affect the quality of sleep, leading to daytime fatigue, mood disturbances, and cognitive impairments. Iranzo et al. (2014) conducted a study revealing that individuals with RBD often suffer from sleep fragmentation and poor sleep quality, contributing to daytime sleepiness and potential depression.

In addition to physical and mental health consequences, untreated RBD can have social implications. The fear and embarrassment about sleep behaviors can lead to social withdrawal or relationship strain. A study by Postuma et al. (2012) noted that the unpredictable nature of the disorder could cause anxiety and stress in both patients and their families, affecting their overall quality of life.

In conclusion, untreated RBD can lead to a range of adverse outcomes, including physical injury, potential development of neurodegenerative diseases, impaired mental health, and social difficulties. These findings underscore the need for early diagnosis and appropriate management of RBD.

Summary

Rapid Eye Movement Sleep Behavior Disorder (RBD) presents a myriad of challenges, both in terms of diagnosis and its impact on individuals' lives. The history of RBD, first described in the 1980s, shows an evolution in understanding and managing this complex disorder. Initially, RBD was not widely recognized, but over the years, increased awareness and research have led to more accurate diagnoses and compassionate approaches to treatment.

Diagnosing RBD is challenging due to its symptoms often being dismissed as nightmares or confused with other sleep disorders. A study by Schenck, Boeve, and Mahowald (2013) highlighted the importance of accurate diagnosis, emphasizing that misdiagnosis can lead to inappropriate treatments and overlooking the potential for neurodegenerative diseases. The development of polysomnography as a diagnostic tool has been crucial, allowing for a more precise understanding and confirmation of RBD.

The evolution in perspective towards RBD has become more inclusive and compassionate, acknowledging the profound impact on patients' identities, relationships, and daily lives. RBD can significantly disrupt relationships, as noted in a study by Iranzo et al. (2014). Partners of individuals with RBD often experience sleep disturbances and may even sustain injuries, leading to strain in relationships. The unpredictable nature of the disorder can also lead to anxiety and embarrassment, affecting patients' social interactions and self-esteem.

RBD’s potential impact on identity and confidence is significant. Postuma et al. (2012) discussed how RBD symptoms could lead to a loss of confidence and self-imposed isolation due to fear of harming others or embarrassment about their sleep behaviors. This can extend into their daily lives, affecting their ability to function effectively at work and in social settings.

In conclusion, RBD is a disorder with far-reaching implications that go beyond the physical symptoms. Its challenging nature lies in its diagnosis and broad impact on individuals' lives. The evolution in understanding and managing RBD reflects a growing awareness of its complexity and the need for holistic approaches to treatment that consider its effects on identity, relationships, and overall quality of life.

References

Boeve, B. F., Silber, M. H., Ferman, T. J., Lin, S. C., Benarroch, E. E., Schmeichel, A. M., ... & Tippmann-Peikert, M. (2013). Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain, 136(Pt 5), 1265-1277.

Frauscher, B., Iranzo, A., Högl, B., Casanova-Molla, J., Salamero, M., Gschliesser, V., ... & Santamaria, J. (2014). Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder. Sleep, 37(3), 529-538.

Frauscher, B., Jennum, P., Ju, Y. E., Postuma, R. B., Arnulf, I., Cochen De Cock, V., ... & Högl, B. (2014). Comorbidity and medication in REM sleep behavior disorder: A multicenter case-control study. Neurology, 82(12), 1076-1079.

Howell, M. J., Schenck, C. H., Crow, S. J. (2011). A review of nighttime eating disorders. Sleep Medicine Reviews, 15(1), 75–86.

Iranzo, A., Fernández-Arcos, A., Tolosa, E., Serradell, M., Molinuevo, J. L., Valldeoriola, F., ... & Santamaria, J. (2014). Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: Study in 174 patients. PLOS ONE, 9(2), e89741.

Iranzo, A., Molinuevo, J. L., Santamaria, J., Serradell, M., Martí, M. J., Valldeoriola, F., ... & Tolosa, E. (2014). Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: A descriptive study. Lancet Neurology, 5(7), 572-577.

Iranzo, A., Tolosa, E., Gelpi, E., Molinuevo, J. L., Valldeoriola, F., Serradell, M., ... & Santamaria, J. (2014). Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study. Lancet Neurology, 13(5), 424-432.

Kunz, D., & Bes, F. (2009). Melatonin as a therapy in REM sleep behavior disorder patients: An update. Journal of Pineal Research, 46(1), 101-110.

McCarter, S. J., St Louis, E. K., Boeve, B. F. (2013). Treatment outcomes in REM sleep behavior disorder. Sleep Medicine Reviews, 17(3), 177–184.

Postuma, R. B., Gagnon, J. F., Vendette, M., Fantini, M. L., Massicotte-Marquez, J., & Montplaisir, J. (2012). Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology, 78(14), 1056-1063.

Postuma, R. B., Lang, A. E., Gagnon, J. F., Pelletier, A., & Montplaisir, J. (2012). How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain, 135(Pt 6), 1860-1870.

Postuma, R. B., Lang, A. E., Massicotte-Marquez, J., Montplaisir, J. (2012). Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology, 78(12), 845-851.

Schenck, C. H., & Mahowald, M. W. (2002). REM sleep behavior disorder: Clinical, developmental, and neuroscience perspectives 16 years after its formal identification in Sleep. Sleep, 25(2), 120-138.

Schenck, C. H., Boeve, B. F., & Mahowald, M. W. (2013). Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: A 16-year update on a previously reported series. Sleep Medicine, 14(8), 744-748.